Cellebrite DI Ltd. (CLBT) SEC Filings & Earnings Calls
EquiReason read 11 Cellebrite DI Ltd. SEC filings in the last 12 months. Latest: 6-K on 2026-09-24 — Routine 6-K reporting results of annual general meeting; shareholder approvals of director elections, executive compensation, auditor reappointment. No material financial or operat.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 3.0B
- P/E TTM
- 52.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
2 Sep 20266-KExplanatory note clarifying dilution figures from proxy statement; no material business event.open
Figures in the filing · each found in the filing text
| Ordinary shares outstanding · 2026-08-01 | 251,341,060 | |
| Fully diluted share count · 2026-08-01 | 276,895,221 | |
| Potential dilution · 2026-08-01 | 9.2% |
Risks flagged
Equity dilution risk clarified at ~9.2% based on fully diluted count; no material change from prior disclosures.
“Potential dilution approximately 9.2% as of August 1, 2026.”
18 Aug 20266-KCellebrite reported record FY2025 results: ARR grew 21% to $480.8M, revenue up 19% to $475.7M, adjusted EBITDA margin 26.8% vs 24.8% prior, FCF $160.3M (34% of revenue). However, Q2 2026 ARR missed expectations due to longer sales cycles inearningsopen
Figures in the filing · each found in the filing text
| Annual Recurring Revenue · FY2025 | $481M | +21% y/y |
| Total Revenue · FY2025 | $476M | +19% y/y |
| Adjusted EBITDA · FY2025 | $128M | |
| Adjusted EBITDA Margin · FY2025 | 26.8% | |
| Free Cash Flow · FY2025 | $160M |
Risks flagged
U.S. Federal business headwinds from leadership, administrative and spending changes
“significant headwinds in our U.S. Federal business stemming largely from leadership, administrative and spending changes within the agencies we serve” · word for word
Q2 2026 ARR miss due to longer sales cycles and additional government procurement requirements
“second-quarter ARR results did not meet our expectations... longer sales cycles, including additional administrative and procurement requirements within certain government opportunities” · word for word
13 Aug 20266-KCellebrite lowers FY26 ARR and revenue outlook due to longer sales cycles and slower Inseyets conversions; raises adjusted EBITDA target on operating discipline.open
Figures in the filing · each found in the filing text
| Annual Recurring Revenue (ARR) · Q2-2026 | $508M | +21% y/y |
| Revenue · Q2-2026 | $131M | +16% y/y |
| Subscription revenue · Q2-2026 | $120M | +16% y/y |
| GAAP gross profit · Q2-2026 | $106M | |
| GAAP gross margin · Q2-2026 | 80.8% | |
| Non-GAAP gross profit · Q2-2026 | $112M | |
| Non-GAAP gross profit margin · Q2-2026 | 85.5% | |
| GAAP net income · Q2-2026 | $6M | |
| Non-GAAP net income · Q2-2026 | $30M | |
| GAAP diluted EPS · Q2-2026 | $0.02 |
Guidance
FY26 ARR lowered to $550M-$560M (from prior); FY26 revenue lowered to $555M-$561M (from prior); FY26 adjusted EBITDA raised to $153M-$159M (from prior); Q3 ARR $524M-$528M; Q3 revenue $145M-$148M; Q3 adjusted EBITDA $42M-$45M.
FY26 ARR and revenue guidance cut due to demand headwinds; EBITDA target raised on cost discipline.
Risks flagged
ARR growth deceleration due to elongated sales cycles and slower Inseyets conversions.
“ARR came in below our expectations. We saw longer sales cycles and less expansion from Inseyets conversions than anticipated.” · word for word
New product contribution may be delayed; measured near-term view.
“we are taking a more measured view of that contribution in the near term, given elongated sales cycles and the timing of additional new product introductions anticipated for later this year.” · word for word
13 Aug 20266-KCEO Thomas E. Hogan stepped down effective August 13, 2026; Shiven Ramji appointed as successor in planned succession. Hogan remains as advisor for 6 months.open
Risks flagged
Leadership transition may cause short-term uncertainty, but planned succession mitigates disruption.
“CEO change effective August 13, 2026; Hogan remains as advisor for 6 months.”
14 May 20266-KQ1 2026 results: ARR $493M (+21% YoY), revenue $128.3M (+19%), subscription revenue $117.9M (+23%), adjusted EBITDA $30.6M (23.9% margin). Q2 outlook highlights ARR acceleration.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $128M | +19% y/y |
| Subscription revenue · Q1-2026 | $118M | +23% y/y |
| Annual Recurring Revenue (ARR) · Q1-2026 | $493M | +21% y/y |
| Dollar-based net retention rate · Q1-2026 | 115.0% | |
| GAAP gross profit · Q1-2026 | $106M | |
| Non-GAAP gross profit · Q1-2026 | $110M | |
| GAAP net income · Q1-2026 | $11M | |
| Non-GAAP net income · Q1-2026 | $31M | |
| GAAP diluted EPS · Q1-2026 | $0.04 | |
| Non-GAAP diluted EPS · Q1-2026 | $0.12 |
3 Mar 202620-FAnnual report (20-F) for fiscal year 2025, no single material event.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents, short-term deposits and marketable securities · FY2025 | $535M | +11% y/y |
| Capital expenditures · FY2025 | $13M | +54% y/y |
| Net cash provided by operating activities · FY2025 | $174M | +31% y/y |
| Research and development spending · FY2025 | $114M | +16% y/y |
Risks flagged
Export license regime change
“On November 18, 2025, the Israeli Minister of Defense signed an order repealing the current encryption control regime and adopting a new regime. The new regime becomes effective on March 18, 2026.” · word for word
Human rights misuse allegations
“In late 2024, Amnesty International published a report alleging that certain law enforcement agencies in Serbia had misused our solutions to access the mobile phones of several journalists and activists and then implanted spyware on those devices.” · word for word
PFIC status uncertainty
“Cellebrite believes that it was not a PFIC and presently does not anticipate that it will be a PFIC based upon the value of its assets, including any goodwill, and the nature and composition of its income and assets. Nevertheless, whether Cellebrite is treated as a PFIC is determined on an annual basis.” · word for word
11 Feb 20266-KRecord Q4 and FY2025 results: ARR $480.8M (+21% YoY), revenue $128.8M (+18%), net income $21.3M, adjusted EBITDA $38.3M (29.8% margin). FY revenue $475.7M (+19%). Announces acquisition of SCG Canada.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $129M | +18% y/y |
| Subscription revenue · Q4-2025 | $116M | +21% y/y |
| Annual Recurring Revenue (ARR) · Q4-2025 | $481M | +21% y/y |
| Dollar-based net retention rate · Q4-2025 | 116.0% | |
| GAAP gross profit · Q4-2025 | $109M | |
| Non-GAAP gross profit · Q4-2025 | $111M | |
| GAAP net income · Q4-2025 | $21M | |
| Non-GAAP net income · Q4-2025 | $37M | |
| GAAP diluted EPS · Q4-2025 | $0.08 | |
| Non-GAAP diluted EPS · Q4-2025 | $0.14 |
Guidance
2026 outlook reflects conviction in accelerated ARR growth
2026 outlook reflects conviction in accelerated ARR growth; positive macro tailwinds.
Risks flagged
U.S. Federal spending environment remains challenging.
“Despite a challenging U.S. Federal spending environment” · word for word
2 Dec 20256-KCellebrite completes acquisition of Corellium for $170M enterprise value ($150M cash, $20M equity, up to $30M earnout). Corellium provides Arm-based virtualization technology for digital investigations.acquisitionopen
Figures in the filing · each found in the filing text
| Enterprise value | $170M |
Risks flagged
Integration risk; CFIUS national security agreement required.
“CFIUS has permitted the acquisition to close on the basis of a national security agreement.” · word for word
12 Nov 20256-KQ3 2025 results: ARR $439.8M (+19% YoY), revenue $126M (+18%), subscription revenue $112.7M (+21%), adjusted EBITDA $37.7M (29.9% margin). U.S. Federal business showed meaningful expansion.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $126M | +18% y/y |
| Subscription revenue · Q3-2025 | $113M | +21% y/y |
| Annual Recurring Revenue (ARR) · Q3-2025 | $440M | +19% y/y |
| Dollar-based net retention rate · Q3-2025 | 117.0% | |
| GAAP gross profit · Q3-2025 | $106M | |
| Non-GAAP gross profit · Q3-2025 | $107M | |
| GAAP net income · Q3-2025 | $20M | |
| Non-GAAP net income · Q3-2025 | $37M | |
| GAAP diluted EPS · Q3-2025 | $0.08 | |
| Non-GAAP diluted EPS · Q3-2025 | $0.14 |
Cellebrite DI Ltd. — questions
- What did Cellebrite DI Ltd. file recently?
- 11 SEC filings in the last 12 months. Latest: 6-K on 2026-09-24 — Routine 6-K reporting results of annual general meeting; shareholder approvals of director elections, executive compensation, auditor reappointment. No material financial or operational event.
Every figure on this page comes from Cellebrite DI Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.